Bill and Danielle Gottfried formed The Kidney Research Institute of Texas to help care for those who are affected by kidney disease and kidney cancer. The Institute was formed in honor of family members who have suffered from and died from kidney disease. 73 million Americans, 1 in 3 American adults, are at risk for developing kidney disease; 30 million Americans, 1 in 9 American adults, are estimated to have chronic kidney disease (CKD), although most do not know it. Over 705,000 Americans have irreversible kidney failure or end state renal disease (ESRD). Source of data: National Institutes of Health, The National Kidney Foundation, and Centers for Disease Control.
Bill and Danielle Gottfried have embarked on a journey to help those in need by supporting kidney disease prevention, kidney disease research, and improvements in patient care, including the acceleration of technology innovation to improve dialysis treatment that remains painful, debilitating, and inhibits the quality of life for those affected. Dialysis technology has not advanced in over 40 years, our goal is to advance technology innovation to improve the quality of life of kidney patients.
The Kidney Research Institute of Texas supports the outstanding research underway worldwide and we will work to capitalize on new scientific discoveries and research that will increase the potential for finding cures and novel candidates for new drug therapies that can prevent and cure kidney disease.
We are initiating a major fundraising campaign in 2021 to support kidney disease prevention, kidney disease research, and technology innovation to improve the lives of kidney patients. We will be working with leading philanthropic, endowment, public and private organizations, sovereign wealth funds, and individuals who are dedicated to ending the global pandemic of kidney disease.
We are committed to finding the cure for kidney disease and for caring for those who are suffering from kidney disease. We look forward to having you join our effort to support the kidney disease patient community , we thank you for your consideration and interest.